ClinicalTrials.gg
RecruitingNCT07481396PCABI-OMICSUpdated Mar 18, 2026

Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics

An observational study in Cardiac Arrest (CA), Cerebrospinal Fluid and Multiomics, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Chungnam National University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Heart Arrest with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Korea, Republic of.

Planned enrollment
16th of 22
60 · median 195
Started
2025
with 2 others
Observational
22 of 44
5 open now
Registered
42nd of 44
by date
Lead sponsor
3 of 44
Chungnam National University Hospital

Among the 44 studies in Heart Arrest with a site in Korea, Republic of, this one is the 16th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, and was the 42nd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

8 of the 44 studies in Heart Arrest with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Heart Arrest with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.

The main question this study aims to answer is:

Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?

To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.

03

Conditions studied

  • Cardiac Arrest (CA)
  • Cerebrospinal Fluid
  • Multiomics
  • Hypoxic-Ischemic Brain Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
  • Patients without for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
  • Uncontrolled diabetes.Coagulation disorders.
  • Thrombocytopenia ( count $\< 100,000).
  • A history of cirrhosis diagnosis.
  • Current receipt of low molecular weight heparin.
  • Current use of platelet inhibitors.
  • A history of posterior spinal fusion that may interfere with catheter insertion.
  • Local skin infection or rash at the puncture site.
  • Signs of systemic infection or sepsis.
  • A history of lumbar puncture within the past 6 hours.

Exclusion criteria

Exclusion Criteria:

  • Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
  • Patients who underwent extracorporeal membrane oxygenation (ECMO).
  • Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
  • Patients with a history of acute or chronic brain disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Favorable neurological outcome

    The favorable neurological outcome group is classified as patients with a CPC score of 1 or 2 upon long-term follow-up (at discharge, 3 months after post-resuscitation)

  • Unfavorable neurological outcome

    The favorable neurological outcome group is classified as patients with a CPC score of 3 to 5 upon long-term follow-up (at discharge, 3 months after post-resuscitation)

06

What researchers measure

Primary outcomes

  1. Neurological outcome

    Neurological outcome assessed using the Cerebral Performance Category (CPC) scale (range 1-5; lower scores indicate better neurological function).

    Time frame: at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Edgren E, Enblad P, Grenvik A, Lilja A, Valind S, Wiklund L, Hedstrand U, Stjernstrom H, Persson L, Ponten U, Langstrom B. Cerebral blood flow and metabolism after cardiopulmonary resuscitation. A pathophysiologic and prognostic positron emission tomography pilot study. Resuscitation. 2003 May;57(2):161-70. doi: 10.1016/s0300-9572(03)00004-2. PubMed 12745184 ↗
  • Buunk G, van der Hoeven JG, Meinders AE. Cerebral blood flow after cardiac arrest. Neth J Med. 2000 Sep;57(3):106-12. doi: 10.1016/s0300-2977(00)00059-0. No abstract available. PubMed 10978556 ↗
  • Madl C, Holzer M. Brain function after resuscitation from cardiac arrest. Curr Opin Crit Care. 2004 Jun;10(3):213-7. doi: 10.1097/01.ccx.0000127542.32890.fa. PubMed 15166839 ↗
  • Wiklund L, Martijn C, Miclescu A, Semenas E, Rubertsson S, Sharma HS. Central nervous tissue damage after hypoxia and reperfusion in conjunction with cardiac arrest and cardiopulmonary resuscitation: mechanisms of action and possibilities for mitigation. Int Rev Neurobiol. 2012;102:173-87. doi: 10.1016/B978-0-12-386986-9.00007-7. PubMed 22748830 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 23 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Mar 18, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Feb 28, 2028
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07481396
Lead sponsor
Chungnam National University Hospital
Responsible party
Changshin Kang (Assistant professor, Chungnam National University Hospital) — Principal investigator
First posted
Mar 18, 2026
Start date
Dec 1, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Changshin Kang, MD. PhD
Contact
rosc@cnu.ac.kr
+821089928386

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion